Clinical Trial Update: Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial of NanoPac in locally advanced pancreatic adenocarcinoma has completed, with results posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• NanoPac (paclitaxel nanoparticle formulation)

Snippet

Sponsor: NanOlogy, LLC | Conditions: Locally Advanced Pancreatic Adenocarcinoma | Phase 2 | Status: COMPLETED | Results posted: 2024-06-24